It has been an exciting year for Rejuvenate Bio. The team has been able to accomplish a number of key goals across both its animal health and human health programs.
- Continued Strong Data in MVD: Through its collaboration with Tufts Veterinary school, Rejuvenate Bio has now shown data out to three years of the effectiveness of its treatment for MVD
- Transformative Partnership: Rejuvenate Bio’s partnership with a leading animal health company for its osteoarthritis program has been incredibly validating of its approach and provides key financial support.
- Manufacturing Breakthrough: A tenfold increase in yields and significant cost reduction position have made gene therapy even more viable for the treatment of MVD and other indications for companion animals
- Strong Strategic Interest in Animal Health: Multiple other parties have also shown interest in partnering with Rejuvenate Bio.
- Scientific Excellence: We generated best-in-class pre-clinical data that sets standards for excellence in Rejuvenate Bio’s lead human indication, laying a solid foundation for future clinical trials.
- Regulatory Validation: Rejuvenate Bio received positive feedback from the FDA on our pre-IND submission, signaling regulatory approval and paving the way for human clinical trials.
- Awarded $4M CIRM Grant for Human Program: With this funding, Rejuvenate Bio will embark on crucial activities to enable the Investigational New Drug (IND) process for its human program, laying the groundwork for clinical trials.
Rejuvenate Bio continues to push the boundaries of what is possible in both animal and human health, driven by scientific excellence and strategic partnerships. We look forward to building on these achievements in the coming year.
